RxDoctor Payments DataLook up a doctor →

David Ellison, MD

Hematology & Oncology · Charleston, SCNPI 1740235928

Payments from drug & device makers

$766,722in general payments, 2019–2025

Across 1,718 payments — averaging $446.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$184K
  • Merck$166K
  • Incyte Corporation$106K
  • Seagen Inc.$87K
  • Regeneron$67K
  • Genentech, Inc.$57K
  • plus $98K from 54 others
$5,788in research payments, 2019–2025

Across 30 payments — averaging $192.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$6K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.112$184,133
Merck127$165,803
Incyte Corporation127$105,968
Seagen Inc.55$86,819
Regeneron46$67,099
Genentech, Inc.17$57,369
United Therapeutics Corporation9$35,211
Astrazeneca UK Limited2$11,560
Pfizer93$10,056
Chiesi USA, Inc.1$6,300
Radius Health, Inc.1$5,657
Puma Biotechnology, Inc.16$3,962
Bristol Myers Squibb58$2,882
Novartis99$1,909
Mirati Therapeutics, Inc.6$1,819
AstraZeneca(2 entities)93$1,696
Genentech USA, Inc.72$1,296
Johnson & Johnson(2 entities)65$1,212
Sanofi43$1,184
Amgen57$1,157
Gilead(2 entities)36$935
Regeneron Healthcare Solutions, Inc.37$788
Lilly USA, LLC38$777
GSK32$700
Takeda Pharmaceuticals U.S.A., Inc.28$665
Eisai Inc.28$526
Jazz Pharmaceuticals Inc.26$494
Astellas Pharma US Inc24$483
Mckesson Specialty Care Distribution, LLC7$466
Daiichi Sankyo Inc.23$458
AbbVie17$402
Taiho Oncology, Inc.17$397
Rigel Pharmaceuticals, Inc.22$393
AVEO Pharmaceuticals, Inc.12$382
Bayer19$367
Sobi, Inc12$262
Tersera Therapeutics LLC10$253
Array Biopharma Inc14$233
Onmark, Inc.1$227
EMD Serono, Inc.11$185
Acrotech Biopharma Inc.8$179
Stemline Therapeutics Inc.6$178
ADC Therapeutics America, Inc.9$177
Novocure Inc.8$174
Ipsen Biopharmaceuticals, Inc7$171
Pharmaessentia USA Corporation8$165
Adaptive Biotechnologies Corporation7$159
Boehringer Ingelheim5$142
Beone Medicines USA, Inc.5$132
Karyopharm Therapeutics Inc.6$132
Servier Pharmaceuticals LLC6$122
Morphosys, US Inc.7$118
Pharmacyclics LLC, An Abbvie Company6$113
Alnylam Pharmaceuticals Inc.5$110
Exelixis Inc.7$105
Deciphera Pharmaceuticals Inc.4$91
Foundation Medicine, Inc.1$89
EUSA Pharma (US) LLC4$85
Springworks Therapeutics, Inc.4$83
Azurity Pharmaceuticals, Inc.3$81

How this compares

$766,722 in reported general payments places this provider in the 90th percentile of 166 hematology & oncology providers in South Carolina.

See all hematology & oncology providers in South Carolina →

Medicare billing

Part B allowed, 2024
$157,764
Medicare patients
537
Services billed
1,601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Charleston

See the full list for South Carolina →

Where these figures come from

Is this you, or does something look wrong? →